JPH11506364A - 血管介入後の血管閉塞の阻害 - Google Patents
血管介入後の血管閉塞の阻害Info
- Publication number
- JPH11506364A JPH11506364A JP8536502A JP53650296A JPH11506364A JP H11506364 A JPH11506364 A JP H11506364A JP 8536502 A JP8536502 A JP 8536502A JP 53650296 A JP53650296 A JP 53650296A JP H11506364 A JPH11506364 A JP H11506364A
- Authority
- JP
- Japan
- Prior art keywords
- matrix
- composition
- cells
- vascular
- endothelial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/069—Vascular Endothelial cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/507—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials for artificial blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/005—Ingredients of undetermined constitution or reaction products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/54—Collagen; Gelatin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Surgery (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Cell Biology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Compounds Of Unknown Constitution (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.血管領域の処置を必要とする患者の血管領域中の血管組織に対する損傷後、 血管の内皮細胞内層の修復を必要とすることなく血管の再狭窄に関連する機構を 阻害する方法における使用のための組成物であって、該方法は、血管組織に対す る損傷または遮断の外部および隣接する部位で、または該血管組織に対する損傷 または遮断において、解離した内皮細胞をその中またはその上に接種されている 生体適合性マトリックスを移植する工程を包含し、該内皮細胞が、該損傷または 遮断の部位で平滑筋細胞増殖を阻害するに十分な量で提供される、組成物。 2.前記損傷が、血管形成術、冠状動脈バイパス手術、抹消バイパス手術、また は器官移植から生じる、請求項1に記載の組成物。 3.前記マリックスが、ゲルまたは泡、懸濁液、マイクロカプセル、固体ポリマ ー基体、または繊維構造からなる群から選択される、請求項1に記載の組成物。 4.前記細胞が、前記マトリックスが移植される患者の生検により得られる、請 求項1に記載の組成物。 5.前記マトリックスが生分解性である、請求項1に記載の組成物。 6.前記マトリックスが、ポリヒドロキシ酸、ポリオルトエステル、ポリアンハ イドライド、タンパク質、炭水化物またはポリサッカライド、ポリホスファゼン 、ポリアルキレンオキシドおよびそれらの組み合わせからなる群から選択される 物質から形成される、請求項5に記載の方法。 7.前記マトリックスが、エチレンビニルアセテート、ポリビニルアルコール、 シリコーン、ポリウレタン、非生分解性ポリエステル、ポリエチレンオキシド- ポリプロピレンオキシド、テトラフルオロエレチンおよびそれらの混合物からな いる群から選択される物質から形成される、請求項1に記載の組成物。 8.前記マトリックスが、抗炎症剤、プロスタグランジン、プロスタノイド、レ ニン-アンギオテンシン軸を制御する化合物、チロシンキナーゼインヒビター、 免疫抑制剤、ビタミン、グルココルチコイド、抗酸化剤、フリーラジカルスカベ ンジャー、ペプチドホルモン、血管新生促進因子および血管新生促進阻害因子、 およびそれらの組み合わせからなる群から選択される生物学的活性化合物をさら に含む、請求項1に記載の組成物。 9.前記細胞が最初にマトリックス中でインビトロ培養され、次いでインビボで 移植される、請求項1に記載の組成物。 10.前記マトリックスが血管のまわりに手術により移植される、請求項1に記 載の組成物。 11.血管の処置を必要とする患者における血管の血管組織に対する損傷の後、 血管の内膜平滑筋細胞増殖または再狭窄を阻害する組成物であって、 血管組織の損傷または遮断の外部および隣接して、または該血管組織の損傷ま たは遮断において、移植に適切な生体適合性マトリックスを含み、 該マトリックスが、その中またはその上に、解離された内皮細胞を、移植後の 平滑筋増殖を阻害するに有効な量で接種されている、組成物。 12.前記量が、血管形成術、冠状動脈バイパス手術、抹消バイパス手術、また は器官移植から生じる損傷を処置するに有効である、請求項11に記載の組成物 。 13.前記マトリックスが、ゲルまたは泡、懸濁液、マイクロカプセル、固体ポ リマー基体、または繊維構造からなる群から選択される、請求項11に記載の組 成物。 14.前記細胞が、同種細胞、同種移植片細胞、異種移植片細胞、および遺伝子 組換え細胞からなる群から選択される、請求項11に記載の組成物。 15.前記マトリックスが生分解性である、請求項11に記載の組成物。 16.前記マトリックスが、ポリヒドロキシ酸、ポリオルトエステル、ポリアン ハイドライド、タンパク質、炭水化物またはポリサッカライド、ポリホスファゼ ン、およびそれらの組み合わせからなる群から選択される物質から形成される、 請求項15に記載の方法。 17.前記マトリックスが、エチレンビニルアセテート、ポリビニルアルコール 、シリコーン、ポリウレタン、非生分解性ポリエステル、ポリエチレンオキシド -ポリプロピレンオキシド、テトラフルオロエレチンおよびそれらの混合物から なる群から選択される物質から形成される、請求項11に記載の組成物。 18.前記マトリックスが、抗炎症剤、プロスタグランジン、プロスタノイド、 レニン-アンギオテンシン軸を制御する化合物、チロシンキナーゼインヒビター 、免疫抑制剤、ビタミン、グルココルチコイド、抗酸化剤、フリーラジカルスカ ベンジャー、ペプチドホルモン、血管新生促進因子および血管新生促進阻害因子 、からなる群から選択される生物学的活性化合物をさらに含む、請求項11に記 載の組成物。 19.前記マトリックス表面が、細胞-マトリックス相互作用を改変するために 修飾されている、請求項11に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US458,978 | 1995-06-02 | ||
US08/458,978 US5766584A (en) | 1995-06-02 | 1995-06-02 | Inhibition of vascular smooth muscle cell proliferation with implanted matrix containing vascular endothelial cells |
PCT/US1996/006707 WO1996038188A1 (en) | 1995-06-02 | 1996-05-09 | Inhibition of vascular occlusion following vascular intervention |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005148802A Division JP2005254000A (ja) | 1995-06-02 | 2005-05-20 | 血管介入後の血管閉塞の阻害 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11506364A true JPH11506364A (ja) | 1999-06-08 |
JP3941881B2 JP3941881B2 (ja) | 2007-07-04 |
Family
ID=23822888
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53650296A Expired - Lifetime JP3941881B2 (ja) | 1995-06-02 | 1996-05-09 | 血管介入後の血管閉塞の阻害 |
JP2005148802A Withdrawn JP2005254000A (ja) | 1995-06-02 | 2005-05-20 | 血管介入後の血管閉塞の阻害 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005148802A Withdrawn JP2005254000A (ja) | 1995-06-02 | 2005-05-20 | 血管介入後の血管閉塞の阻害 |
Country Status (8)
Country | Link |
---|---|
US (1) | US5766584A (ja) |
EP (1) | EP0850073B1 (ja) |
JP (2) | JP3941881B2 (ja) |
AT (1) | ATE232748T1 (ja) |
AU (1) | AU714559B2 (ja) |
CA (1) | CA2222497C (ja) |
DE (1) | DE69626290T2 (ja) |
WO (1) | WO1996038188A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004523537A (ja) * | 2001-01-16 | 2004-08-05 | ヴァスキュラー セラピーズ リミテッド ライアビリティ カンパニー | 吸収可能なマトリックス材料および抗増殖薬を含む、血液透析血管アクセス及び他の血管移植片の機能不全を防止又は治療するための移植可能な装置および方法 |
JP2008522735A (ja) * | 2004-12-08 | 2008-07-03 | パーバシス セラピューティクス, インコーポレイテッド | 血管アクセスを強化するための方法および組成物 |
JP2008546406A (ja) * | 2005-06-21 | 2008-12-25 | パーバシス セラピューティクス, インコーポレイテッド | 脈管アクセスを改善するための方法および組成物 |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE339975T1 (de) | 1993-07-19 | 2006-10-15 | Angiotech Pharm Inc | Anti-angiogener stent und verfahren zu dessen herstellung |
ATE302599T1 (de) | 1996-05-24 | 2005-09-15 | Angiotech Pharm Inc | Zubereitungen und verfahren zur behandlung oder prävention von krankheiten der körperpassagewege |
US20020077564A1 (en) * | 1996-07-29 | 2002-06-20 | Farallon Medsystems, Inc. | Thermography catheter |
US20080305999A1 (en) * | 1996-11-01 | 2008-12-11 | John Francis Martin | Therapeutic use of growth factor, and delivery device, especially for the treatment of intimal hyperplasia |
US20040015069A1 (en) * | 1996-12-27 | 2004-01-22 | Brown David Lloyd | System for locating inflamed plaque in a vessel |
US20030039694A1 (en) * | 1998-04-28 | 2003-02-27 | Martin John Francis | Periadventitial delivery device |
GB9809082D0 (en) * | 1998-04-28 | 1998-06-24 | Eurogene Limited | Delivery device |
US6375680B1 (en) * | 1998-12-01 | 2002-04-23 | St. Jude Medical, Inc. | Substrates for forming synthetic tissues |
US20040097990A1 (en) * | 1999-01-27 | 2004-05-20 | Zhao Iris Ginron | Graft material, device & method of making |
US6824549B1 (en) * | 2000-06-07 | 2004-11-30 | Iris Ginron Chao | Method & device for making reversed bypass with cultured vessel in situ |
US6333347B1 (en) | 1999-01-29 | 2001-12-25 | Angiotech Pharmaceuticals & Advanced Research Tech | Intrapericardial delivery of anti-microtubule agents |
US6328762B1 (en) * | 1999-04-27 | 2001-12-11 | Sulzer Biologics, Inc. | Prosthetic grafts |
US6921412B1 (en) | 1999-05-18 | 2005-07-26 | Cryolife, Inc. | Self-supporting, shaped, three-dimensional biopolymeric materials and methods |
JP3603179B2 (ja) | 1999-09-09 | 2004-12-22 | グンゼ株式会社 | 心血管系組織培養用基材および組織再生法 |
CA2396628A1 (en) | 2000-01-25 | 2001-08-02 | Edwards Lifesciences Corporation | Delivery systems for treatment of restenosis and anastomotic intimal hyperplasia |
WO2002034111A2 (en) | 2000-10-24 | 2002-05-02 | Cryolife, Inc. | In situ bioprosthetic filler and methods, particularly for the in situ formation of vertebral disc bioprosthetics |
US20040241211A9 (en) * | 2000-11-06 | 2004-12-02 | Fischell Robert E. | Devices and methods for reducing scar tissue formation |
JP4199004B2 (ja) | 2000-11-07 | 2008-12-17 | クライオライフ、インコーポレイテッド | 起泡性泡沫様生体材料および方法 |
JP3970013B2 (ja) * | 2001-12-14 | 2007-09-05 | 泰晴 野一色 | 管腔形成誘導性材料および体内挿入用器具 |
WO2003093433A2 (en) * | 2002-05-02 | 2003-11-13 | Regents Of The University Of Minnesota | Fibrin-based biomatrix |
JP4265888B2 (ja) * | 2002-06-12 | 2009-05-20 | 株式会社リコー | 画像形成装置 |
EP1610823B1 (en) | 2003-03-28 | 2011-09-28 | Innovational Holdings, LLC | Implantable medical device with continuous agent concentration gradient |
US7416546B2 (en) * | 2003-05-05 | 2008-08-26 | Boston Scientific Scimed, Inc. | Tissue patches and related delivery systems and methods |
US8034048B2 (en) * | 2003-05-05 | 2011-10-11 | Boston Scientific Scimed, Inc. | Tissue patches and related delivery systems and methods |
US8192348B2 (en) * | 2003-07-01 | 2012-06-05 | Regents Of The University Of Minnesota | Engineered blood vessels |
WO2005007034A1 (en) | 2003-07-08 | 2005-01-27 | The Children's Hospital Of Philadelphia | Steroid lipid-modified polyurethane as an implantable biomaterial, the preparation and uses thereof |
AU2004281694B2 (en) * | 2003-10-10 | 2012-05-03 | Cellular Bioengineering, Inc. | Methods and compositions for growing corneal endothelial and related cells on biopolymers and creation of artifical corneal transplants |
US20050245905A1 (en) * | 2004-04-30 | 2005-11-03 | Schmidt Steven P | Local drug-delivery system |
AU2011211370B2 (en) * | 2004-12-08 | 2013-08-15 | Shire Regenerative Medicine, Inc. | Methods and compositions for enhancing vascular access |
AU2006238892B2 (en) | 2005-04-21 | 2011-01-27 | Massachusetts Institute Of Technology | Materials and methods for altering an immune response to exogenous and endogenous immunogens, including syngeneic and non-syngeneic cells, tissues or organs |
US20070100323A1 (en) * | 2005-10-31 | 2007-05-03 | Ludwig Florian N | Facilitation of endothelialization by in situ surface modification |
US20100204783A1 (en) * | 2005-12-06 | 2010-08-12 | Helen Marie Nugent | Methods and compositions for enhancing vascular access |
US20100092532A1 (en) * | 2006-11-07 | 2010-04-15 | Helen Marie Nugent | Materials and Methods for Treating and Managing Angiogenesis-Mediated Diseases |
US20080176206A1 (en) | 2007-01-18 | 2008-07-24 | Toshiharu Shinoka | Cardiovascular tissue culture substrate |
ES2381641T3 (es) * | 2007-06-13 | 2012-05-30 | Pervasis Therapeutics, Inc. | Métodos y dispositivos para la administración mínimamente invasiva de composiciones fluidas que contienen células |
WO2009061334A1 (en) * | 2007-11-06 | 2009-05-14 | Massachusetts Institute Of Technology | Tissue-engineered endothelial and epithelial implants differentially and synergistically regulate tissue repair |
US20110218606A1 (en) * | 2010-03-02 | 2011-09-08 | Medtronic Vascular, Inc. | Methods for Stabilizing Femoral Vessels |
US9114235B2 (en) | 2010-05-03 | 2015-08-25 | Cardiovascular Systems, Inc. | Therapeutic agent delivery system and method for localized application of therapeutic substances to a biological lumen |
FR2960784B1 (fr) | 2010-06-04 | 2012-07-20 | Univ Claude Bernard Lyon | Nouveaux substituts vasculaires biodegradables |
US9198975B2 (en) | 2010-12-01 | 2015-12-01 | The University Of North Carolina At Chapel Hill | Methods and compositions for targeting sites of neovascular growth |
CN111454467B (zh) * | 2020-02-18 | 2022-07-12 | 中国人民大学 | 一种涂抹式生物可降解血管外支架及其制备方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4418691A (en) * | 1981-10-26 | 1983-12-06 | Massachusetts Institute Of Technology | Method of promoting the regeneration of tissue at a wound |
US4787900A (en) * | 1982-04-19 | 1988-11-29 | Massachusetts Institute Of Technology | Process for forming multilayer bioreplaceable blood vessel prosthesis |
IL78950A (en) * | 1985-06-06 | 1991-12-15 | Univ Jefferson | Coating for prosthetic devices |
US5567612A (en) * | 1986-11-20 | 1996-10-22 | Massachusetts Institute Of Technology | Genitourinary cell-matrix structure for implantation into a human and a method of making |
WO1991007154A1 (en) * | 1989-11-13 | 1991-05-30 | President And Fellows Of Harvard College | EXTRALUMINAL REGULATION OF THE GROWTH AND REPAIR OF TUBULAR STRUCTURES ιIN VIVO |
US5527532A (en) * | 1989-11-13 | 1996-06-18 | President And Fellows Of Harvard College | Extraluminal regulation of the growth and repair of tubular structures in vivo |
US5540928A (en) * | 1991-02-27 | 1996-07-30 | President And Fellows Of Harvard College | Extraluminal regulation of the growth and repair of tubular structures in vivo |
WO1993002188A1 (en) * | 1991-07-15 | 1993-02-04 | Oklahoma Medical Research Foundation | Universal donor cells |
US5336615A (en) * | 1992-01-06 | 1994-08-09 | Yale University | Genetically engineered endothelial cells exhibiting enhanced migration and plasminogen activator activity |
US5399665A (en) * | 1992-11-05 | 1995-03-21 | Massachusetts Institute Of Technology | Biodegradable polymers for cell transplantation |
JPH09512184A (ja) * | 1994-04-29 | 1997-12-09 | ダブリュ.エル.ゴア アンド アソシエイツ,インコーポレイティド | 内皮下細胞外基質上の内皮を利用する改善された血液接触表面 |
-
1995
- 1995-06-02 US US08/458,978 patent/US5766584A/en not_active Expired - Lifetime
-
1996
- 1996-05-09 DE DE69626290T patent/DE69626290T2/de not_active Expired - Lifetime
- 1996-05-09 CA CA002222497A patent/CA2222497C/en not_active Expired - Lifetime
- 1996-05-09 WO PCT/US1996/006707 patent/WO1996038188A1/en active IP Right Grant
- 1996-05-09 AU AU62928/96A patent/AU714559B2/en not_active Expired
- 1996-05-09 EP EP96915700A patent/EP0850073B1/en not_active Expired - Lifetime
- 1996-05-09 JP JP53650296A patent/JP3941881B2/ja not_active Expired - Lifetime
- 1996-05-09 AT AT96915700T patent/ATE232748T1/de not_active IP Right Cessation
-
2005
- 2005-05-20 JP JP2005148802A patent/JP2005254000A/ja not_active Withdrawn
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004523537A (ja) * | 2001-01-16 | 2004-08-05 | ヴァスキュラー セラピーズ リミテッド ライアビリティ カンパニー | 吸収可能なマトリックス材料および抗増殖薬を含む、血液透析血管アクセス及び他の血管移植片の機能不全を防止又は治療するための移植可能な装置および方法 |
JP2009119257A (ja) * | 2001-01-16 | 2009-06-04 | Vascular Therapies Llc | 吸収可能なマトリックス材料および抗増殖薬を含む、血液透析血管アクセス及び他の血管移植片の機能不全を防止又は治療するための移植可能な装置および方法 |
JP2008522735A (ja) * | 2004-12-08 | 2008-07-03 | パーバシス セラピューティクス, インコーポレイテッド | 血管アクセスを強化するための方法および組成物 |
JP2008532565A (ja) * | 2004-12-08 | 2008-08-21 | パーバシス セラピューティクス, インコーポレイテッド | 細胞含有流動性組成物の最小侵襲投与のための材料および方法 |
JP2012176260A (ja) * | 2004-12-08 | 2012-09-13 | Pervasis Therapeutics Inc | 血管アクセスを強化するための方法および組成物 |
JP2013056202A (ja) * | 2004-12-08 | 2013-03-28 | Pervasis Therapeutics Inc | 血管アクセスを強化するための方法および組成物 |
JP2008546406A (ja) * | 2005-06-21 | 2008-12-25 | パーバシス セラピューティクス, インコーポレイテッド | 脈管アクセスを改善するための方法および組成物 |
Also Published As
Publication number | Publication date |
---|---|
CA2222497A1 (en) | 1996-12-05 |
JP3941881B2 (ja) | 2007-07-04 |
JP2005254000A (ja) | 2005-09-22 |
EP0850073A1 (en) | 1998-07-01 |
DE69626290D1 (de) | 2003-03-27 |
EP0850073B1 (en) | 2003-02-19 |
DE69626290T2 (de) | 2003-12-04 |
AU6292896A (en) | 1996-12-18 |
AU714559B2 (en) | 2000-01-06 |
ATE232748T1 (de) | 2003-03-15 |
US5766584A (en) | 1998-06-16 |
CA2222497C (en) | 2008-07-29 |
WO1996038188A1 (en) | 1996-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3941881B2 (ja) | 血管介入後の血管閉塞の阻害 | |
US11938246B2 (en) | Tissue-based compositions and methods of use thereof | |
Nathan et al. | Tissue engineered perivascular endothelial cell implants regulate vascular injury. | |
US6291240B1 (en) | Cells or tissues with increased protein factors and methods of making and using same | |
EP2184077B1 (en) | Materials and methods for minimally-invasive administration of a cell-containing flowable composition | |
KR101650957B1 (ko) | 세포외 기질 조성물 | |
Edelmana et al. | Perivascular graft heparin delivery using biodegradable polymer wraps | |
JP2002501513A (ja) | 心筋瘢痕への移植体および方法ならびにそのための細胞調製物 | |
Geer et al. | In vivo model of wound healing based on transplanted tissue-engineered skin | |
JPH07508663A (ja) | 臓器移植のための予備血管新生されたポリマー性移植片 | |
JPH11503946A (ja) | ヒアルロン酸誘導体を基本とするバイオ適合性物質を支持体として含む人工皮膚 | |
IL145892A (en) | Three-dimensional stromal tissue | |
Christenson et al. | Tissue reaction to intraperitoneal polymer implants: species difference and effects of corticoid and doxorubicin | |
JPH07102130B2 (ja) | 人工マトリックスを用いる制御された細胞移植による器官のキメラ新生形態形成 | |
HU228887B1 (hu) | Keratinociták, melyek felhasználhatók biológiailag aktív anyagként sebek kezelésénél | |
JP2002506344A (ja) | ヒアルロン酸誘導体を支持体とする細胞培養および生分解性三次元マトリクス | |
Cass et al. | Scar wars: implications of fetal wound healing for the pediatric burn patient | |
JP3333108B2 (ja) | 上皮性組織移植片およびその製造方法 | |
EP1096940B1 (en) | Biocompatible and biodegradable compositions containing hyaluronic acid and the derivatives thereof for the treatment of ulcers in the digestive apparatus | |
Ryo et al. | 023 Development of Tissue Engineering Skin Based on Acellular Dermal Matrix | |
Mizuno et al. | Promising therapy for congenital giant pigmented nevi using acellular autograft nevi-dermal matrix | |
Kent et al. | Preliminary evaluation of a technique for inhibiting intimal hyperplasia: Implantation of a resorbable luminal collagen membrane | |
Geer | Tissue engineered models of skin regeneration for the design and evaluation of drug release systems | |
Hideyuki et al. | 019 2 Cases of Mediastinitis After Median Sternotomy Surgery Treated with Vacuum‐Assisted Closure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20031205 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040126 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040309 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050222 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050520 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20051220 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060124 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070227 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070328 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110413 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120413 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120413 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130413 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130413 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140413 Year of fee payment: 7 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |